Investigating a protein that may help treat a severe intestinal condition in newborns
Official title: Inter-alpha Inhibitors in Experimental Necrotizing Enterocolitis
Funded at Prothera Biologics, LLC · NIH-10822492 · Data updated 2026-11-12
This study is looking at how a special protein might help reduce inflammation in the intestines of premature babies with a serious condition called necrotizing enterocolitis (NEC), with the hope of finding better treatments to improve their health and survival.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Prothera Biologics, LLC NIH-funded |
| Lab location | 1 site (Providence, United States) |
| Project start | September 22, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $378,272 |
| NIH project number | 1R43HD114348-01 |
| Project ID | NIH-10822492 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are premature infants who are at risk of developing necrotizing enterocolitis.
✕Less likely to help
Patients who are not premature or do not have a diagnosis of necrotizing enterocolitis may not benefit from this research.
What this research studies
This research focuses on necrotizing enterocolitis (NEC), a serious inflammatory condition affecting the intestines of premature infants. The study aims to explore the role of inter-alpha inhibitor proteins (IAIP) in modulating the inflammatory response associated with NEC. By understanding how IAIP can potentially reduce inflammation and improve outcomes, the research seeks to develop new therapeutic strategies. Patients may benefit from treatments that target inflammation more effectively, potentially leading to better survival rates and health outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce the morbidity and mortality associated with necrotizing enterocolitis in newborns.
How similar studies have gone: While the approach of using IAIP in treating inflammatory conditions is promising, this specific application in necrotizing enterocolitis is still under investigation and has not been widely tested.
Where this research is happening
-
Prothera Biologics, LLC
Providence, United States Active
Researchers
- Principal investigator: Lim, Yow-Pin — Prothera Biologics, LLC
- Study coordinator: Lim, Yow-Pin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.